| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17425247.2014.911728 |
| P698 | PubMed publication ID | 24754747 |
| P50 | author | Thomas Rades | Q37828574 |
| Petra Alexandra Priemel | Q57041544 | ||
| Line Hagner Nielsen | Q59544201 | ||
| Riikka Laitinen | Q114445996 | ||
| Holger Grohganz | Q39864868 | ||
| Korbinian Löbmann | Q40692383 | ||
| P2093 | author name string | Guy Van den Mooter | |
| Anette Mullertz | |||
| P2860 | cites work | A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability | Q28293773 |
| Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution | Q30992178 | ||
| Fast surface crystallization of amorphous griseofulvin below T g. | Q33562887 | ||
| Amorphous pharmaceutical solids: preparation, characterization and stabilization | Q34233896 | ||
| Spatial confinement can lead to increased stability of amorphous indomethacin | Q34240950 | ||
| A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals | Q34665881 | ||
| Melt extrusion: from process to drug delivery technology | Q34793080 | ||
| Glasses crystallize rapidly at free surfaces by growing crystals upward | Q34794288 | ||
| Modification of the solid-state nature of sulfathiazole and sulfathiazole sodium by spray drying | Q35999134 | ||
| Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA. | Q36331520 | ||
| Mesoporous silicon: a platform for the delivery of therapeutics | Q36750143 | ||
| Review: physical chemistry of solid dispersions | Q37643840 | ||
| Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems | Q37942798 | ||
| Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. | Q51933789 | ||
| Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study. | Q52599984 | ||
| A comparative study of the effect of spray drying and hot-melt extrusion on the properties of amorphous solid dispersions containing felodipine. | Q54342599 | ||
| Miniaturized screening of polymers for amorphous drug stabilization (SPADS): Rapid assessment of solid dispersion systems | Q57360710 | ||
| In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) | Q58199076 | ||
| Inhibition of surface crystallisation of amorphous indomethacin particles in physical drug–polymer mixtures | Q59234458 | ||
| Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions | Q59234583 | ||
| Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin | Q59234607 | ||
| The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin | Q59234647 | ||
| Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling | Q59235070 | ||
| Stability of amorphous pharmaceutical solids: crystal growth mechanisms and effect of polymer additives | Q37995510 | ||
| Mesoporous systems for poorly soluble drugs | Q38044590 | ||
| Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates | Q38050160 | ||
| Drug precipitation-permeation interplay: supersaturation in an absorptive environment | Q39306982 | ||
| Pharmaceutical Applications of Solid Dispersion Systems | Q40000294 | ||
| Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. | Q40294237 | ||
| Characteristics and significance of the amorphous state in pharmaceutical systems | Q41323277 | ||
| Effect of counterions on the properties of amorphous atorvastatin salts | Q41607145 | ||
| Surface-enhanced crystallization of amorphous nifedipine | Q42162153 | ||
| Solubilities of crystalline drugs in polymers: an improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP/VA, and PVAc | Q42979593 | ||
| Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate | Q43006891 | ||
| Theoretical and experimental investigation on the solid solubility and miscibility of naproxen in poly(vinylpyrrolidone). | Q43044276 | ||
| Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and eudragit e100. | Q43145360 | ||
| Aqueous film coating to reduce recrystallization of guaifenesin from hot-melt extruded acrylic matrices | Q43251738 | ||
| Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs | Q43252837 | ||
| Fusion processing of itraconazole solid dispersions by kinetisol dispersing: a comparative study to hot melt extrusion | Q43291975 | ||
| A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin | Q43753649 | ||
| Evaluation of the structural determinants of polymeric precipitation inhibitors using solvent shift methods and principle component analysis. | Q43782639 | ||
| Characterization of carbamazepine-Gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. | Q43938194 | ||
| Evaluation of drug supersaturation by thermodynamic and kinetic approaches for the prediction of oral absorbability in amorphous pharmaceuticals | Q43957967 | ||
| Biorelevant characterisation of amorphous furosemide salt exhibits conversion to a furosemide hydrate during dissolution | Q44183555 | ||
| Stabilisation of amorphous drugs under high humidity using pharmaceutical thin films. | Q44365106 | ||
| Coamorphous repaglinide-saccharin with enhanced dissolution | Q44516449 | ||
| A method to predict the equilibrium solubility of drugs in solid polymers near room temperature using thermal analysis | Q44686991 | ||
| Phase behavior of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility | Q45117919 | ||
| Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats | Q45394825 | ||
| Cocrystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir. | Q45398135 | ||
| Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement | Q45811011 | ||
| Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. | Q45918887 | ||
| Anomalous properties of spray dried solid dispersions. | Q46004482 | ||
| Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation | Q46069091 | ||
| Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions. | Q46318738 | ||
| Improved physical stability of amorphous state through acid base interactions | Q46330466 | ||
| Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation | Q46471158 | ||
| Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen | Q46481214 | ||
| In situ amorphisation of indomethacin with Eudragit® E during dissolution | Q46546738 | ||
| The effect of pressurized carbon dioxide as a temporary plasticizer and foaming agent on the hot stage extrusion process and extrudate properties of solid dispersions of itraconazole with PVP-VA 64. | Q46683024 | ||
| Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions | Q47275244 | ||
| Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size | Q47385833 | ||
| Bulk, surface properties and water uptake mechanisms of salt/acid amorphous composite systems. | Q50474793 | ||
| Impact of process variables on the micromeritic and physicochemical properties of spray-dried microparticles--Part II. Physicochemical characterisation of spray-dried materials. | Q50489339 | ||
| Impact of process variables on the micromeritic and physicochemical properties of spray-dried porous microparticles, part I: introduction of a new morphology classification system. | Q50489341 | ||
| Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. | Q51372033 | ||
| Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions. | Q51441001 | ||
| Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. | Q51542358 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 977-989 | |
| P577 | publication date | 2014-04-23 | |
| P1433 | published in | Expert Opinion on Drug Delivery | Q5421203 |
| P1476 | title | Refining stability and dissolution rate of amorphous drug formulations | |
| P478 | volume | 11 |
| Q114864269 | A Novel Curcumin-Based Drug Powder Inhalation Medicine for Chronic Obstructive Pulmonary Disease |
| Q57353648 | Characterization of amorphous solid dispersions |
| Q58691868 | Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia |
| Q88741018 | Confinement of Amorphous Lactose in Pores Formed Upon Co-Spray Drying With Nanoparticles |
| Q57785804 | Dual mechanism of microenvironmental pH modulation and foam melt extrusion to enhance performance of HPMCAS based amorphous solid dispersion |
| Q51284615 | Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion. |
| Q92891800 | Identification and investigation of the vibrational properties of crystalline and co-amorphous drugs with Raman and terahertz spectroscopy |
| Q51105115 | On the inherent properties of Soluplus and its application in ibuprofen solid dispersions generated by microwave-quench cooling technology. |
| Q38907190 | Porous calcium carbonate as a carrier material to increase the dissolution rate of poorly soluble flavouring compounds. |
| Q59234241 | Properties of the Sodium Naproxen-Lactose-Tetrahydrate Co-Crystal upon Processing and Storage. |
| Q38856865 | Rational excipient selection for co-amorphous formulations |
| Q37371404 | Stable Colloidal Drug Aggregates Catch and Release Active Enzymes |
| Q36408457 | The Binary System of Ibuprofen-Nicotinamide Under Nanoscale Confinement: From Cocrystal to Coamorphous State. |
| Q38644728 | The Precipitation Behavior of Poorly Water-Soluble Drugs with an Emphasis on the Digestion of Lipid Based Formulations. |
| Q38856754 | The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers. |
Search more.